Regulus Therapeutics
RGLS
#7010
Rank
โ‚ฌ0.48 B
Marketcap
7,07ย โ‚ฌ
Share price
0.00%
Change (1 day)
407.81%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚ฌ44.02 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚ฌ40.04 Million a decrease over its 2023 earnings that were of -โ‚ฌ25.51 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚ฌ44.02 Million9.94%
2024 -โ‚ฌ40.04 Million56.97%
2023 -โ‚ฌ25.51 Million6.51%
2022 -โ‚ฌ23.95 Million2.53%
2021 -โ‚ฌ23.36 Million93.59%
2020 -โ‚ฌ12.07 Million-15.41%
2019 -โ‚ฌ14.27 Million-64.46%
2018 -โ‚ฌ40.13 Million-33.26%
2017 -โ‚ฌ60.13 Million-13.98%
2016 -โ‚ฌ69.9 Million44.77%
2015 -โ‚ฌ48.29 Million-1.63%
2014 -โ‚ฌ49.09 Million203.6%
2013 -โ‚ฌ16.17 Million8.65%
2012 -โ‚ฌ14.88 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚ฌ6.67 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ1.34 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ8.08 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ12.22 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ8.57 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚ฌ94.49 Million 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚ฌ0.11 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ0.49 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA